All Updates

All Updates

icon
Filter
Funding
BenchSci raises CAD 95 million Series D funding
AI Drug Discovery
May 25, 2023
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Product updates
Partnerships
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
AI Drug Discovery

AI Drug Discovery

May 25, 2023

BenchSci raises CAD 95 million Series D funding

Funding

  • Toronto-based AI drug discovery company BenchSci has raised CAD 95 million (USD 70 million) in a Series D funding round led by Generation Investment Management, with participation from existing investors iNovia Capital and TCV, among others.

  • The proceeds will be directed toward further developing and expanding the capabilities of the company’s proprietary AI platform, ASCEND. The platform, which is currently being used by over 50,000 scientists, is reportedly capable of expediting the pre-clinical testing of novel drug targets by reducing trial-and-error and identifying potential problems sooner.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.